Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis.
about
Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we?Hepatitis C: efficacy and safety in real life.The potential of signal peptide peptidase as a therapeutic target for hepatitis C.Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection.
P2860
Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Current drugs in early develop ...... irus-related hepatic fibrosis.
@en
type
label
Current drugs in early develop ...... irus-related hepatic fibrosis.
@en
prefLabel
Current drugs in early develop ...... irus-related hepatic fibrosis.
@en
P2860
P50
P1476
Current drugs in early develop ...... irus-related hepatic fibrosis.
@en
P2093
Dariusz Lebensztejn
P2860
P304
P356
10.1517/13543784.2015.1057568
P407
P577
2015-06-30T00:00:00Z